IV NAD+: Does It Really Work Better Than Oral NMN or NR?

In our entry on NMN, we describe how oral NAD+ precursors (NMN, NR) must pass through gut absorption and first-pass liver metabolism before reaching the bloodstream and being used by cells to rebuild NAD+ levels. That's a natural starting point for the marketing argument behind IV NAD+ infusions: if we skip the gut and inject NAD+ itself directly into the blood, we should deliver more active compound directly where it's needed, without absorption losses.

NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide — a relatively large, electrically charged molecule. Cell membranes are inherently selectively permeable and generally don't freely let large, charged molecules through — they need dedicated membrane transporters for that. This isn't a controversial biochemical claim, but a basic physicochemical property of the NAD+ molecule itself, independent of whether it's delivered orally or intravenously.

What's more, extracellular NAD+ — whether naturally circulating in blood or delivered by IV infusion — is subject to surface enzymes such as CD38 and CD73, which actively break it down into smaller components (including nicotinamide and other intermediate metabolites) while still outside the cell, before the molecule would have a chance to enter it intact. This means that even if an IV infusion effectively raises blood NAD+ concentration — which is relatively easy to measure and probably true — that isn't the same as proof that cells throughout the body take up that NAD+ in its unchanged, active form.

This doesn't automatically mean intravenous NAD+ is worthless — it means the central pharmacokinetic argument used to sell it is much weaker than commonly presented, since it rests on an assumption (intact transport of the whole molecule into the cell) that hasn't been confirmed by direct human evidence, and existing biochemical knowledge of NAD+ transport across cell membranes rather argues against that assumption.

Intravenous NAD+ infusions at longevity and wellness clinics are significantly more expensive than oral supplementation with NAD+ precursors like NMN or NR, described in our NMN entry as one of the pricier segments of the supplement market. A single IV NAD+ session (usually lasting from one to several hours, sometimes spread across several visits per week) typically costs in the hundreds, and with longer protocols — thousands of złoty per month, i.e., many times more than monthly supplementation with oral NMN or NR.

The central marketing argument for intravenous NAD+ — that it bypasses digestive limits and delivers the active compound directly to cells — is biochemically incomplete, because it ignores a well-understood barrier at the cell membrane itself, independent of the route of administration. The only available human pharmacokinetic study confirms that NAD+ is detectable and metabolized after infusion, but doesn't settle the key question of intracellular uptake. Combined with a significantly higher cost and added procedural risk, current evidence doesn't support the claim that IV NAD+ "works better" than well-studied oral precursors — that claim remains an unproven marketing hypothesis, not an established pharmacological fact.